There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Xeris Pharmaceuticals (XERS) and Verastem (VSTM) with bullish sentiments.
Xeris Pharmaceuticals (XERS)
Mizuho Securities analyst Difei Yang maintained a Buy rating on Xeris Pharmaceuticals today and set a price target of $18.00. The company’s shares closed last Monday at $1.69, close to its 52-week low of $1.42.
According to TipRanks.com, Yang has currently no stars on a ranking scale of 0-5 stars, with an average return of -20.7% and a 26.2% success rate. Yang covers the Healthcare sector, focusing on stocks such as Revance Therapeutics, Nektar Therapeutics, and Akebia Therapeutics.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Xeris Pharmaceuticals with a $18.00 average price target.
See today’s analyst top recommended stocks >>
Verastem (VSTM)
In a report released today, Matthew Cross from JonesTrading upgraded Verastem to Buy, with a price target of $3.50. The company’s shares closed last Monday at $1.86.
According to TipRanks.com, Cross has currently no stars on a ranking scale of 0-5 stars, with an average return of -10.2% and a 26.4% success rate. Cross covers the Healthcare sector, focusing on stocks such as Actinium Pharmaceuticals, Catalyst Biosciences, and Aldeyra Therapeutics.
Verastem has an analyst consensus of Strong Buy, with a price target consensus of $4.10, which is a 153.1% upside from current levels. In a report issued on March 16, H.C. Wainwright also reiterated a Buy rating on the stock with a $2.80 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
